Biopretium

Here's a fresh new role for my network - I am currently partnered with a European based, technology led services business who partner with businesses in the biopharma space, providing cutting edge consulting and Clinical Trial Simulation services. We're looking for a Senior Pharmacometrician who is excited to approach modelling in a different way, utilising AI powered technology and Big Data into their Clinical Trial Simulation projects. If this sounds like you then I'd love to hear from you. The role can be remote anywhere in Europe. P.S. We're also partnering with this business to appoint a Project Manager for this business so if you are an experienced PM with knowledge of the PKPD & PBPK space then do reach out! chris.gibson@biopretium.com

Leadership transitions are inevitable. In the fact paced world of Life Sciences, keeping the momentum going is crucial. Here are a few things you can do to try and prevent disruption to your ongoing clinical development programs. 𝐄𝐚𝐫𝐥𝐲 𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐢𝐨𝐧 𝐏𝐥𝐚𝐧𝐧𝐢𝐧𝐠 Identify and develop future leaders early to keep the ball rolling when change happens. Regularly refresh your succession plans to stay ahead of the game as the industry evolves. 𝐒𝐭𝐫𝐞𝐚𝐦𝐥𝐢𝐧𝐞𝐝 𝐎𝐧𝐛𝐨𝐚𝐫𝐝𝐢𝐧𝐠 Get new leaders up to speed quickly with a deep dive into the company’s culture, projects, and goals. Even better, you can begin doing this during the latter stages of an interview process (which will help you to secure the hire) Connect them with key players right away to fast-track relationship-building and decision-making. 𝐂𝐥𝐞𝐚𝐫, 𝐎𝐩𝐞𝐧 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧 Keep internal leaders in the loop during the transition to avoid confusion and ensure a smoother integration. By keeping these in mind, you can turn leadership transitions into opportunities for growth and innovation. How do you manage leadership changes in your business? Let’s hear your tips and stories below! 👇 #LeadershipTransitions #LifeSciences #ExecutiveLeadership #SuccessionPlanning #Innovation

Biopharma VC funding surges to $9.2 Billion in Q2 2024. A sign of resilience? Venture capital funding in biopharma soared to $9.2 billion across 215 deals in Q2 2024, marking the highest level since Q2 2022. While this boost reflects renewed confidence, it's driven by mega-rounds in AI and obesity, leaving some other firms struggling. However, the drop in exits, from $10 billion in Q1 to $4.5 billion in Q2, suggests challenges ahead. IPOs and M&A are slowing, with companies holding onto their assets longer. As we navigate these mixed signals, it's clear that identifying leaders who can thrive in this volatile environment will be crucial for sustained growth and innovation. #Biopharma #VentureCapital #Leadership #Innovation #LifeSciences

Happy July 4th to colleagues, clients, candidates and friends out in the USA. Fun fact: July 4th also happens to be my birthday, so I will be doing much the same as my US friends this evening - BBQ and Beer.

(Sourced via Reza Zahiri on X…) Quite incredible growth in revenues, and some who took me by surprise, like Sinopharm…